Summary
The purpose of this study is to compare the usual treatment (enzalutamide) alone to using rucaparib plus the usual treatment. The addition of rucaparib to the usual treatment could make patients live longer, or prevent cancer from growing or spreading for a longer time, or both.
Keywords
oncology, cancer, tumor, treatment, prostate, metastatic
Categories
Cancer
Cancer - Prostate and Urologic
Description
Principal Investigator
Study Coordinator
Megan Ware
Research Contact
Megan Ware - megan.ware@vandaliahealth.org
Departments
Sex
Male
Age
18+
NCT Number
NCT4455750
IRB Number
22-843
Phase(s)
3
Link
None